UniCAR is a universal CAR-T platform that can be rapidly turned ... Two ATAC assets are now in clinical trials: GEM333, which binds to the CD33 cancer antigen, is in a phase 1a study for the ...

CAMBRIDGE, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period and full ...

with the potential to enable targeted therapies such as Mylotarg and CD33-targeted CAR-T therapy post-transplant, while avoiding on-target toxicities. The latest data update from VBP101 ...